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1. Introduction 
There are various sources of stem cells which are being studied for their potential in stem 
cell–based therapies for CNS diseases (Yu D & Silva, 2008):  
1.1 Embryonic stem cells 
Embryonic stem cells are pluripotent cells with indefinite self-renewal capabilities as well as 
the ability to differentiate into all cell types derived from the 3 embryonic germ layers (How 
Embryonic, 2010). Embryonic stem cells are favorable in the research community because 
they are relatively easy to isolate, can grow indefinitely, and have the potential to develop 
into any type of adult cell. 
1.2 Adult stem cells  
Adult stem cells (ASCs) play a critical role in tissue maintenance and repair (Stem Cell 
Basics, 2010). Research on adult stem cells began in the 1950s with the discovery of 
multipotent hematopoietic and mesenchymal stem cells in bone marrow, which can 
generate a number of tissues (Stem Cell Basics, 2010). Bone Marrow-Derived Mesenchymal 
Stem Cells can be expanded and differentiated in vitro using various media formulations 
and culture surface conditions to direct them to different cell lineages (Ho et al., 2006). 
BMSCs have the ability to migrate to areas of injury, even crossing the blood-brain barrier 
(Akiyama et al., 2002; Tang et al., 2007). Although the reproducibility of BMSC therapies 
needs to be thoroughly examined, these early experiments suggest that BMSCs can be 
administered intravenously to CNS targets. (Rice & Scolding, 2008) 
1.3 Neural stem cells 
The adult mammalian CNS contains NSCs which were first inferred from evidence of 
neuronal turnover in the olfactory bulb and hippocampus in the adult. (Altman & Das, 1965, 
1966). Neural stem cells are able to differentiate into neurons, astrocytes, oligodendrocytes 
and various forms of neural precursors (Flax et al.,1998;Gage,2000;Palmer et 
al.,1997;Takahashi et al.,1999;Weiss et al.,1996) .Moreover, in vivo delivery of these cells to 
animal models of neurodegenerative diseases was associated with varying degrees of 
functional recovery (Ourednik et al.,2002). Figure (1) (Lindvall & Kokaia., 2006) 
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Fig. 1. Application of stem cells for neurogical disorders. Steam cells would be isolated and 
transplanted to the diseased brain and spinal cord, either directly or after 
predifferentiation/genetic modification in culture to form specific types of neuron and glial 
cell, or cells producing neuroprotective molecules. In strategies relying on stimulation of the 
patient’s own repair mechanisms, endogenous stem cells would be recruited to areas of the 
adult brain and spinal cord affected by disease, where they would produce new neurons 
and glia (neurogenetic and gliogenic areas along lateral ventricle and central canal are 
shown in hatched red). Stem cells could provide clinical benefits by neuronal replacement, 
remyelination and neuroprotection. 
2. Strategies for using stem cells to treat neurological disorders  
These include strategies in which:  
i. Stem cells are transplanted within the brain, are infused by blood circulation (Figure 2); 
or delivered through bone marrow transplantation (BMT; Figure 2). 
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ii. Stem cells are stimulated by cytokines, or trophic and growth factors, into the brain in 
vivo; 
iii. Stem cells are engineered to correct the genetic defect (Figure 2), delivery of therapeutic 
agents.  
iv. Stem cells are combined with biomaterials (Figure 2).  
 http://www.discoverymedicine.com/Antonio-Orlacchio/ n.d 
 
 
Fig. 2. Stem cells replacement therapy for neurological diseases. Cartoon schematizes the 
different strategies for stem cell delivery in order to repair the degenerated tissue. 
http://www.discoverymedicine.com/Antonio-
Orlacchio/files/2010/06/discovery_medicine_orlacchio_no49_figure 
2.1 Cell replacement through transplantation of exogenous cells 
Transplantated donor cells into a host organism offer the chance to expand and manipulate 
cells in vitro. This method has proven successful in the haematopoietic system. Such  
method to be successful in the CNS the transplanted cells must (1) survive the 
transplantation; (2) migrate to the site of replacement; (3) differentiate into appropriate cell 
phenotype(s); and (4) make appropriate connections with the host tissue.  
The condition is further complicated during neurodegenerative disease, since the same 
factors that cause mature neurons to die (oxidative stress, accumulation of toxic protein 
aggregates, etc.), may also lead to cell death in transplanted cells. There are a number of 
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criteria for improving the opportunities for successful cell replacement using transplanted 
cells. Generally, selecting cells from the same region as the region to which the cells will be 
transplanted increases the transplantation success rate. (Tobi& Mahendra., 2005) 
2.2 Mobilization of endogenous stem cells 
A second therapeutic approach is the mobilization of endogenous cells to replace lost or 
damaged cells . The production of new neurons (neurogenesis) occurs at a very low rate in 
the adult brain, in two regions: the subventricular zone of the lateral ventricle, which 
produces new neurons of the olfactory bulb, and in the hippocampus. Neurogenesis can be 
stimulated in the adult brain by factors, including diet, exercise and modification of 
hormone levels. (Tobi& Mahendra., 2005) 
Moreover, neurogenesis can be stimulated in the adult brain by growth factors, such as 
epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF).However, delivery 
of these factors is complicated, since growth factors are large molecules that cannot 
penetrate the blood–brain barrier when it is intact. Transfer of growth factors into the adult 
CNS can be accomplished through direct injection into the brain and/or the ventricles 
within the brain or through transplantation of cells genetically engineered to secrete growth 
factors into the surrounding environment. Additionally, growth factors can be used to 
protect endogenous NPCs neural progenitor cells from dying. (Tobi& Mahendra., 2005) 
2.3 Delivery of therapeutic agents 
Drug Delivery to the CNS is complicated by the blood–brain barrier, which prevents many 
large, hydrophilic molecules from entering the brain through the bloodstream. One 
potential use of NPCs neural progenitor cells is as delivery agents for pharmacological 
compounds . A large number of studies provides evidence that delivery of supportive 
factors can slow the degeneration process in several neurodegenerative diseases. Although 
this method has many problems, including controlling the survival rate of transplanted cells 
and controlling the rate of drug secretion, this is one path currently being explored for 
therapy using stem cells. (Tobi& Mahendra., 2005) 
2.4 Stem cells are combined with biomaterials  
Tissue engineering approach includes the transplantation of stem cells in combination with 
natural or synthetic biomaterials (Dawson et al., 2008). Verification came from data showing 
that chemical and biological modifications of biomaterials could directly influence stem cell 
behavior (e.g., change of substrate properties, nanopattern design, scaffold degradation rate) 
(Atala, 2009; Martino et al., 2009).  
3. Stem cells for different neurological disorders 
The use of stem cells in neurological diseases is much more complex than in other systems. 
Many challenges are unique to the nervous system are as follows: (a) The need to integrate 
into a sophisticated array of interconnected cells that extend over great distances; (b) The 
absence of developmental cues in adults that guided the establishment of neural networks 
during development, thus making regeneration more difficult; (c) The possibility in 
progressive or recurrent neurologic diseases that the transplanted cells may be attacked and 
injured (Potter et al, 2007) 
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3.1 Parkinson’s disease 
A widespread loss of dopamine neurons (DA) in the substantia nigra pars compacta and 
their terminals in the striatum occurs in Parkinson’s disease (PD) (Kish et al., 1988; Agid, 
1991). Many issues for the dopaminergic depletion associated with the disease have been 
suggested, including programmed cell death, viral infection, and environmental toxins. As 
an efficient treatment for PD, patients have been given L-dihydroxyphenyl alanine (L-
DOPA), a precursor of dopamine, but long-term administration of L-DOPA consequently 
produces side effects (Lang and Lozano, 1998 a, b). So, human fetal ventral mesencephalic 
tissues were transplanted of into the striatum of PD patients as a successful therapy for 
patients with advanced disease, since the late 1980s (Lindval et al., 1990; Olanow et al., 1996; 
Kordower et al, 1997; Dunnett and Bjorklund, 1999). This fetal tissue transplantation has 
serious problems associated with ethical and religious questions and logistics of acquiring 
fetal tissues (Hagell et al., 1999). To avoid these difficulties, utilization of neurons with a DA 
phenotype generated from ESCs, MSCs, or NSCs could serve as a practical and effective 
alternative for fetal brain tissues for transplantation. DA neurons were generated from 
mouse ESCs or mouse NSCs (Lee et al., 2000; Hagell & Brundin, 2002; J.H. Kim et al., 2002; 
T.E. Kim et al., 2003). Neural cells with a DA phenotype have been generated from monkey 
ESCs by coculturing with mouse bone marrow stromal cells (Takagi et al., 2005) and also 
from human NSCs derived from fetal brain (Redmond et al., 2007), and improvement was 
seen in MPTP lesioned monkeys following intrastriatal transplantation of these cells (Takagi 
et al., 2005; Redmond et al., 2007).  
NSCs which were transplanted in the brain attenuate anatomic or functional deficits 
associated with injury or disease in the CNS via cell replacement, release of specific 
neurotransmitters, and production of neurotrophic factors that protect injured neurons and 
promote neuronal growth. Recently, continuously dividing immortalized cell lines of 
human NSC have been generated from fetal human brain cell culture via a retroviral vector 
(Kim, 2004; Lee et al., 2007; Kim et al., 2008), and one of the immortalized NSC lines, 
induced functional improvement in a rat model of PD following transplantation into the 
striatum (Yasuhara et al., 2006). 
3.2 Alzheimer’s disease 
Alzheimer disease is characterized by degeneration and loss of neurons and synapses 
throughout the brain, particularly in the basal forebrain, amygdala, hippocampus, and 
cortical area. Cognitive function of patients progressively declines, and patients become 
demented and die prematurely (Coyle et al., 1983). No successful treatment is currently 
available except for acetylcholinesterase inhibitors, which augment cholinergic function, but 
this is not curative and is only a temporary measure.  
A recent study has reported that Nerve growth factor (NGF) prevents neuronal death and 
improves memeory in animal models of aging, excitotoxicity, and amyloid toxicity 
(Tuszynski, 2002), suggesting that NGF may be used for treating neuronal degeneration and 
cell death in AD. However, convey of NGF into the brain is not possible via peripheral 
administration; because of its size and polarity, NGF does not cross the blood–brain barrier. 
To avoid this difficulty, gene therapy approach could be adopted. By utilizing an ex vivo 
gene therapy approach (genetically modify cells), NGF can be given directly to the brain and 
diffuse for a distance of 2–5 mm (Tuszynski et al., 1990).  
Ex vivo NGF gene delivery was clinically tried in eight mild-AD patients, implanting 
autologous fibroblasts genetically modified to express human NGF into the forebrain. After 
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follow-up of 22 months in six subjects, long-term adverse effects were not found. PET scans 
showed significant increases in cortical fluorodeoxyglucose after treatment (Tuszynski et al., 
2005). Genetically modified stem cells could be used in place of fibroblasts to carry new 
genes for delivery of NGF to prevent degeneration of basal forebrain cholinergic neurons 
(Flax et al., 1998; Kim, 2004; Lee et al., 2007, Kang et al., 1993). 
A blood stem cell growth factor (granulocyte-colony stimulating factor (G-CSF) is routinely 
administered to cancer patients whose blood stem cells and white blood cells have been 
depleted following chemotherapy or radiation. the bone marrow was stimulated by G-CSF 
to produce more white blood cells needed to fight infection; and  is also used to enhance the 
stem cells circulating in the blood of donors before the cells are harvested for bone marrow 
transplants. (Pavlović et al., 2009; Lee et al., 2010) 
Advanced clinical trials are now investigating the effectiveness of G-CSF to treat stroke, and 
the compound was safe and well tolerated in early clinical studies of ischemic stroke 
patients. This growth factor could potentially provide a powerful new therapy for 
Alzheimer’s disease that may actually reverse disease, not just alleviate symptoms like 
currently available drugs(Ramos & Raj., 2009). The researchers showed that injections under 
the skin of filgrastim (Neupogen®) - one of three commercially available G-CSF compounds 
- mobilized blood stem cells in the bone marrow and neural stem cells within the brain and 
both of these actions led to improved memory and learning behavior in the Alzheimer’s 
mice on the basis of reactive microglia derived from stem cells that are destroying deposits 
of amyloid plaques in brain tissue. So far, a human growth factor that stimulates blood stem 
cells to proliferate in the bone marrow reverses memory impairment in mice genetically 
altered to develop Alzheimer’s disease (Ramos & Raj., 2009).  The G-CSF significantly 
reduced levels of the brain-clogging protein beta amyloid deposited in excess in the brains 
of the Alzheimer’s mice increased the production of new neurons and promoted nerve cell 
connections. 
Researchers at the Kyungpook National University in Daegu, South Korea, tested the 
potential therapeutic effects of bone marrow-derived MSCs in mice. The 2009 study was 
able to successfully confirm that BM-MSC transplantation accelerated the removal of 
amyloid-ǃ plaques from the brains of acute AD mice, this study also showed that the BM-
MSCs can induce normally-quiescent microglia to clear out amyloid-ǃ build-up (Lee et al., 
2009). The three professors who performed the 2009 study in Korea reported in early 2010 
that the decreased amyloid-ǃ deposition was directly related to microglial activation (Lee et 
al., 2010). They also showed that the microglia ameliorate memory deficiencies in the AD 
mice. This finding was supported by a version of the Morris water maze test known as the 
hidden platform. Subjects which received PBS injections deteriorated as expected in their 
ability to learn and memorize the maze, while those treated with BM-MSCs displayed 
navigational patterns that resembled control subjects. Moreover, they reported that the MB-
MSC transplantation was able to reduce tau hyperphosphorylation (Lee et al., 2010).  
3.3 Huntington’s disease 
A neurodegenerative disorder (Huntington’s disease (HD) is characterized by involuntary 
choreiformic movements, cognitive impairment, and emotional disturbances (Greenmayre 
and Shoulson, 1994; Harper, 1996). In spite of identification of the HD gene and associated 
protein, the mechanisms involved in the pathogenesis of HD remain largely unknown.  
A recent research has documented improvements in motor and cognition performance in 
HD patients following fetal cell transplantation (Bachaud-Le´vi et al., 2000). This research 
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follows previous reports on experimental HD animals that positive effects of fetal striatal 
cell transplantation ameliorate neuronal dysfunction (Nakao and Itakura, 2000) and that 
striatal graft tissue could integrate and survive within the progressively degenerated 
striatum in a transgenic HD mouse model (Dunnett et al., 1998; Freeman et al., 2000). 
A restrictive factor in the transplantation of fetal striatal cells is the difficulty in supplying 
sufficient amounts of embryonic striatal tissue and the concomitant ethical issues associated 
with the use of human embryonic tissue. A perfect source of cell transplantation in HD 
would be NSCs, which could participate in normal CNS development and differentiate into 
regionally appropriate cell types in response to environmental factors. Prior studies have 
shown that NSCs isolated from embryonic or adult mammalian CNS can be propagated in 
vitro and subsequently implanted into the brain of animal models of human neurological 
disorders, including HD (Brustle and McKay, 1996; Flax et al., 1998; Gage, 2000; Temple, 
2001; Gottlieb, 2002; Lindvall and Kokaia, 2006).  
Genetically modified NSCs producing neurotrophic factors and transplantation of NSCs to 
replace degenerated neurons have been used to protect striatal neurons against excitotoxic 
insults (Bjorklund and Lindvall, 2000).  
Recently, human NSCs were injected intravenously to counteract neural degeneration in HD 
model rats and demonstrated functional recovery in grafted animals (Lee et al., 2005, 2006).  
3.4 Amyotrophic Lateral Sclerosis 
3.4.1 Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by 
progressive dysfunction and degeneration of motor neurons occur not only in the spinal 
cord (lower motor neurons) but also in the cerebral cortex and brainstem (upper motor 
neurons). Muscle weakness progresses rapidly and death occurs within a few years. There 
are currently no effective treatments for ALS (Wolfson et al,2009). 
 The expectation for ALS patients is that stem cell transplantation will replace motor 
neurons, leading to the recovery of neuromuscular functions. Unfortunately, the expectation 
that stem cells will play such a regenerative role in patients with ALS is unrealistic because 
of the complexity of the task, a more realistic expectation for stem cells is that they play a 
supportive role in maintaining the viability of or extending the function of surviving motor 
neurons (Silani et al,2002). 
Inducing stem cells to differentiate into supporting cells, glia, or interneurons that might 
produce factors that would support motor neurons, or perhaps the stem cells themselves 
might produce such factors (Svendsen et al,2004) . 
3.4.2 Stem cells for treating ALS: current developments 
3.4.2.1-Neural stem cells (NSCs) is a challenging therapeutic strategy for treatment of ALS. 
To provide insight into the potential of the intravenous delivery of NSCs, Mitrecić, and his 
colleagues, (2010) evaluated the delivery of NSCs marked with green fluorescent protein to 
the central nervous system (CNS) via intravenous in an ALS model. Highly efficient  cell 
delivery to the CNS was found in symptomatic ALS (up to 13%), moderate in 
presymptomatic ALS (up to 6%), and was the lowest in wild animals (up to 0.3%). The study 
provides basic facts about the process occurring after NSCs leave the blood stream and enter 
the nervous tissue affected by inflammation or degeneration, which should help facilitate 
the planning of future bench-to-bedside translational projects. 
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3.4.2.2-Haemopiotic stem cell : Preliminary trials with autologous hematopoietic stem cells 
have been reported in humans. In one, peripheral blood-purified CD34+ cells were injected 
intrathecally into 3 patients with ALS (Appel et al,2008, Janson et al 2001)) None reported 
side effects after 6-12 months, but no clinical efficacy was reported. In another, Deda and 
collaborators(2009) reported follow-up results one year after stem cell transplantation. The 
post-operative status of nine patients indicate a significant improvement in comparison to 
the pre-operative status, as confirmed by electroneuromyography. 
3.4.2.3-Mesenchymal bone marrow stem cell: are currently used as an alternative therapy in 
amyotrophic lateral sclerosis (ALS) patients. Cho, et al 2010 isolated BM-SCs from 11 ALS 
patients and characterized their potential secretory capacity of neurotrophic factors and they 
noticed that ALS-SCs have diminished capacity as trophic mediators and may have reduced 
beneficial effects in cell therapy& suggested that MSCs at early passages are more suitable 
for stem cell therapy in ALS patients because of their stability and more potent anti-
inflammatory and neuroprotective properties (Choi, et al,2010). 
Marzzini 2003 ,study the effect intraspinal transplantation of MSCs on 7 patients , Minor 
postoperative adverse events were transient, but muscle strength continued to decline. 
Three months later, however, the investigators reported a trend toward slowing of the 
decline in the proximal muscle groups of the lower limb in 4 patients and a mild increase in 
strength in 2 patients. The absence of placebo controls and longer follow-up preclude any 
inferences of efficacy from this study. Karussis and his collauge 2010, prove in phase I trial 
using intrathecal with or without intravenous MSCs in patients with ALS, Transplantation is  
clinically feasible and relatively safe procedure with stability of the mean Amyotrophic 
Lateral Sclerosis Functional Rating Scale [ALSFRS] score. 
3.4.2.4- Induced pluripotent stem cell: The generation of pluripotent stem cells from an 
individual patient would enable the large-scale production of the cell types affected by the 
patient's disease, using induced pluripotent stem (iPS) cells overcomes the ethical problems 
of using embryos. (John et al,2008) can  make  reprogramming of human fibroblasts  to 
induced pluripotent stem (iPS) cells from skin biopsy of an 82-year-old woman diagnosed 
with a familial form of amyotrophic lateral sclerosis (ALS). These patient-specific iPS cells 
possess properties of embryonic stem cells, they were successfully directed to differentiate 
into motor neurons, the cell type destroyed in ALS.  
These preliminary hope needs to be tempered with caution because of the early stages of 
stem cell research in general, and in ALS in particular. 
3.5 Spinal Muscular Atrophy 
Spinal muscular atrophies (SMA) present a heterogenic group of hereditary neurological 
diseases and one of the types of motor neuron disease.  It is a common “rare disorder”, 
affecting approximately 1 in 6000 babies born, to date no cure exists. The primary 
approaches to treating or curing SMA have now focused on two strategy options, the first, 
genetic therapy - manipulating the genetic material responsible for producing SMA. While 
the second is cellular replacement therapy - replacing dead or dying motor neurons. 
Stem cell strategies are presently under investigation, although significant preclinical work 
and methodological advances remain ahead before these approaches can become clinically 
relevant (Douglas et al; 2010). 
 The goal of transplantation is providing a pool of cells that are able to support endogenous 
neurons through delivery of neuroprotective factors and providing a replacement 
population for lost motor neurons. In Vitro Stem-cell-derived motor neurons have been 
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shown to grow axons and successfully form neuromuscular junctions (Gao et al;2007, 2005; 
Wichterle et al;2002), and stem cell transplants have lead to growth of axons and some 
recovery in paralyzed rats (Deshpande et al;2006; Harper et al; 2004). Induced pluripotent 
stem cells have been derived from patients with SMA and used to generate motor neurons 
that show selective deficits compared with wild-type motor neurons in culture (Ebert et 
al;2009).  
Spinal-cord-derived neural stem cells have been successfully transplanted into the mouse 
model of SMA, with a modest improvement of the clinical phenotype and generation of a 
viable population of motor neurons (Corti et al;2008). 
A subsequent study using pluripotent stem cells demonstrated similar successful stem cell 
engraftment and differentiation with improved survival and functional improvement in 
treated SMA Model compared with controls, demonstrating the therapeutic potential of this 
approach (Corti et al; 2010). 
Although these reports suggest the possibility of stem cell therapy, several challenges must 
be addressed before the successful implementation of stem cell therapy can be fully realized. 
For this strategy to be applicable, large numbers of stem cells need to be generated, to 
successfully populate the nervous system, properly differentiate into motor neurons and, 
critically, must successfully and correctly extend axons to and synapse upon muscle targets. 
It still remains unclear when this therapeutic strategy will become a practical approach in 
the treatment for SMA in the human population. 
3.6 Brain tumor 
Despite extensive surgical excision and radiotherapy and chemotherapy; malignant brain 
tumors such as glioblastoma multiforme remain virtually untreatable and lethal (Black and 
Loeffler, 1997). The opposition to treatment is associated with their exceptional migratory 
nature and ability to insinuate themselves seamlessly and extensively into normal brain 
tissue, often migrating great distances from the primary tumor masses(Dunn and Black, 
2003; Sanai et al., 2005). Medulloblastoma is the most common among childhood brain 
tumors and is incurable. Available treatments including radical surgical resection followed 
by radiation and chemotherapy have substantially improved the survival rate in this 
disease; however, it remains incurable in about one-third of patients (Packer et al., 1999). As 
well, in the case of recurrence, frequently associated with tumor dissemination and the main 
cause of death, therapeutic options are rarely available (Patrice et al., 1995; Graham et al., 
1997).  
The capability of human NSCs as an effective delivery system to target and disseminate 
therapeutic agents to medulloblastomas was demonstrated for the first time (Kim et al., 
2006). One of the causes for the recurrence of medulloblastoma in children after standard 
treatment is the inherent tendency of tumor cells to metastatize through cerebrospinal fluid, 
leading to leptomeningeal dissemination. Throughout the entire spinal cord, human NSC 
F3.CD cells were found to distribute diffusely to metastatic medulloblastoma cells after 
injection in the cisterna magna, and the CD gene in NSCs functioned effectively and killed 
tumor cells (Shimato et al., 2007). 
3.7 Temporal lobe epilepsy 
Current studies have shown that transplanted neurons can restore neurogenesis (Kuruba et 
al., 2009), and GABAergic neurons can reduce seizures (Alvarez-Dolado et al., 2006). 
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Moreover, one study has shown that a specific type of “stem cell,” transplanted into the 
dentate gyrus often matures into normal GCs, which could be used in a restorative manner 
if neurogenesis declines (Carpentino et al., 2008). Remarkably, these stem cells can lead to 
abnormal growths if a normal animal is used, but in an animal that has had seizures, the 
stem cells become GCs and tumors do not appear to develop (Carpentino et al., 2008). 
Infusion of neuropeptide Y may be a particularly effective strategy after such stem cell 
infusion, because it stimulates precursor division (Howell et al., 2003; Scharfman and Gray, 
2006;  2007) and reduces seizures (Noe et al., 2006). 
There are four distinct stem cell-based approaches for treating TLE. The first approach 
involves development of methods for inhibiting increased proliferation of hippocampal 
NSCs during the first few weeks following the SE. Addressing this issue is important in 
light of studies suggesting that epileptic seizures such as SE not only increase dentate 
neurogenesis but also lead to abnormal migration of newly born granule cells into the 
dentate, where they exhibit spontaneous epileptiform bursts and may contribute to the 
development of chronic epilepsy (Dashtipour et al., 2001; Parent et al., 2006).  
The second approach focuses on developing strategies that activate endogenous NSCs in the 
chronically epileptic hippocampus to produce a large number of new neurons including 
GABA-ergic interneurons. This approach has significance because studies in both TLE and 
animals models of TLE suggest that chronic TLE is associated with dramatically declined 
production of new neurons in the adult DG. Decreased neurogenesis during chronic 
epilepsy may contribute to the persistence of seizures possibly due to decreased addition of 
new GABA-ergic interneurons.  
The third strategy comprises rigorous analyses of the efficacy of grafts of NSCs placed into 
the hippocampus after the onset of chronic epilepsy for suppressing seizures and learning 
and memory deficits. This is because the initial results of stem cell grafting studies in TLE 
models reported (Shetty & Hattiangady.,2006, Acharya et al.,2007) are promising in terms of 
their short term survival and their effectiveness for reducing the frequency of seizures and  
findings of delivery of anticonvulsant compounds such as NPY, glial-derived neurotrophic 
factor, and adenosine is efficacious for reducing seizures in animal models of TLE (Noe et 
al., 2007; Li et al., 2007). 
A fourth approach would be a combination therapy comprising NSC cell transplants and 
cell or recombinant viral vector-based delivery of anticonvulsant compounds into the 
hippocampus during chronic epilepsy. This plan may be very efficient, as seizure control 
would likely be mediated by both GABA-ergic interneurons derived from NSC transplants 
and anti-convulsant compounds released by genetically engineered cells. (Shetty& 
Hattiangady., 2007) 
3.8 Lysosomal storage diseases 
Most affected babies by lysosomal storage diseases show a diffuse CNS involvement 
(Meikle et al., 1999). At present, no effective treatment is available for most of the lysosomal 
diseases, because the blood–brain barrier bars entry of enzyme preparations into the brain 
(Sly and Vogler, 2002). However, therapeutic levels of enzymes could be achieved in the 
brain of animal models of lysosomal diseases by direct inoculation of genetically engineered 
mouse (Snyder et al., 1995), fibroblasts (Taylor and Wolfe, 1997), or amniotic epithelial cells 
(Kosuga et al., 2001). In consideration of their widespread migratory ability, normal or 
genetically modified stem cells would allow widespread delivery of missing enzymes all 
over the brain. In a mouse model of mucopolysaccharidosis VII (MPS VII), a lysosomal 
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disease caused by a genetic defect in the activity of b-glucuronidase (b-gluc), genetically 
engineered mouse overexpressing b-gluc were transplanted into the cerebral ventricle and 
resulted in reduction of lysosomal storage in the mouse brain (Snyder et al., 1995). Similarly, 
the transplantation of (b-gluc) overexpressing human NSCs into MPS VII mice and human 
NSCs migrated extensively all over the brain, produced high levels of b-gluc enzyme, and 
cleared lysosomal storage in the neuronal cytoplasm (Meng et al., 2003). In an earlier study, 
immortalized human NSCs were transplanted in a mouse model of Tay-Sachs disease in 
which abnormal lysosomal storage of GM2 ganglioside is found in the brain, resulting from 
total absence of hexosaminidase enzyme activity. After transplantation of human NSCs, 
there was a clearance of storage in neuronal cytoplasm in Tay-Sachs model mice (Flax et al., 
1998). The results indicate that NSCs could serve as an excellent gene transfer vehicle for the 
treatment of diffuse CNS pathology in human lysosomal storage diseases, including Krabbe 
disease, Gaucher’s disease, metachromatic leukodystrophy, and adrenoleucodystrophy. 
3.9Multiple sclerosis  
3.9.1 Introduction  
MS is a chronic, demyelinating disease of the brain and spinal cord ,MS is heterogeneous 
disease, and so the degree of the disease can range from fairly benign to extremely 
debilitating and the stages of disease can range from only relapses to progressive (Weiner 
;2009) 
Unfortunately, the available treatments  (Immunomodulatory and immunosuppressive)are 
not curative, they can reduce CNS inflammation and may delay progression, but control of 
disease is unsatisfactory in many patients ,a logical treatment approach to enhance 
neuroprotective mechanisms and to induce neuroregeneration through  stem cell 
transplantation, stem cell therapy for MS can categorize to immune reconstruction or tissue 
reconstruction  (remylination),two distinct approaches can be considered to promote myelin 
repair, in one the endogenous myelin repair processes are stimulated through the delivery 
of growth factors, and in the second the repair process are augmented through the delivery 
of exogenous cells with myelination potential. Also, the effective treatment of MS requires 
modulation of the immune system, since demyelination is associated with specific 
immunological activation  (Karussis & Kassis; 2007 ) 
Several types of stem cells having the capacity for promoting myelin repair, as well as 
modulating the immune response, are potential candidates for MS therapy( Emily et 
al;2007). 
3.9.2 Stem Cells for treating MS: current developments 
3.9.2.1 Embryonic stem cells (ESCs) 
When transplanted in rodent models of induced demyelination, embryonic stem cells were 
shown able to differentiate into glial cells and re-ensheath demyelinated axons in vivo 
(Brustle etal,1999 ; McDonald et al;1999). Researchers have underlined that ESCs could be a 
“double-edged sword” since they may  cause the formation of a non-homologous implant 
and teratomas within the organ of transplantation (Brustle etal;1999, Deacon etal,1998;,Yanai 
et al;1995). 
3.9.2.2 Adult stem cells 
can be detected in both fetuses, and adults. They can be harvested from different tissues: 
adipose tissue (Gimble& Guilak ;2003), bone-marrow (hematopoietic-HSC (Wognum et 
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al;2003), mesenchymal-MSC (Pittenger,1999 ; Prockop etal;1997), CNS (neural stem cells-
NSC, neurospheres) , olfactory bulb (Roisen et al;2001) and others. Several studies suggested 
the neuroregenerative, the immunomodulatory potential of these adult stem cells (puissant 
etal;2005 ,Yu et al;2006). 
3.9.2.2.1 Adult neural stem cells (NSCs) 
In a study by Pluchino et al; 2003 it was shown that adult neural stem cells cultured and 
injected into EAE-mice—intravenously (iv) or intracerebroventricularly (icv), could migrate 
into the demyelinating CNS area and differentiate into mature brain cells. It was apparent in 
this study, that oligodendrocyte progenitors were especially increased, in this model. 
Clinically, EAE symptoms were strongly down-regulated in the transplanted animals. 
Despite these promising results,  NSC are still not considered the perfect stem cell 
population for cell replacement therapy and are associated with significant drawbacks. The 
difficulty is in culturing neurospheres from regions of the adult brain that do not normally 
undergo self-renewal (Shihabuddin etal;2000) neurosphere-derived cells do not necessarily 
behave as stem cells when transplanted back into the brain  and thus form a focus for 
immune rejection. 
3.9.2.2.2 Hematopoietic stem cells  
Autologous Hematopoietic stem cells (HSCT) was largely preferred to allogeneic 
transplantation because of the lower risk of severe toxicity (van Gelder & van Bekkum; 
1995). Briefly, patients with autoimmune diseases can be considered for HSCT if: (i) their 
disease is severe enough to cause an increased risk of mortality or advanced and irreversible 
disability; (ii) the disease has been unresponsive to conventional treatments, so, Fassas and 
his collaeuge; 2003 recommended practice points to AHSCT for MS patients 
(a) AHSCT seems to be the best anti-inflammatory treatment as evidenced in MRI scans. Its 
clinical value remains to be validated in controlled trials.(b) MS types characterized by 
neurodegenerative pathogenic components are unlikely to benefit from ASCT.(c) Good 
candidates are young patients with rapidly evolving RR-MS or ‘‘malignant’’ MS. Also, 
patients with SP-MS having EDSS scores below 6.5, evidence of inflammation in the CNS, 
and clinical worsening during the last year.(d)Intense conditioning or extensive T depletion 
increase the morbidity & mortality risk  
3.9.2.2.3 Mesenchymal stem cells (MSCs) 
initially isolated from bone marrow but are now shown to reside in almost every type of 
connective tissue (Da silva etal; 2006). The use of bone marrow derived MSC provides 
several advantages over conventional neuronal, embryonic and hematopoietic stem cells: (1) 
they can be obtained from the adult bone marrow; (2) they can be easily cultured and 
expanded in large numbers; (3) they can be injected autologously without the need of 
immunosuppressive means to risk for induction of malignancies, as compared to other types 
of stem cells  prevent rejection; and (4) they are less prone to genetic abnormalities during 
multiple in vitro passages these cells have been shown to have diff eren tiation capacities as 
well as paracrine eff ects via the secretion of growth factors, cytokines, antifi brotic or 
angiogenic mediators (Djouad et al ; 2009). A large body of studies also indicates that MSCs 
possess an immunosuppressive function both in vitro and in vivo (Karussis &  Kassis; 2008). 
How mesenchymal stem cells affect functional recovery in the damaged adult CNS is not 
well understood. Fig (3)  represent MSC Potential for Therapeutic Applications in 
autoimmune disorders 
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They have therefore been tested in the EAE ( Ren et al ;2009) MSCs were shown to decrease 
the clinical signs associated with demyelination when injected before or at the onset of the 
disease, thus demonstrating the therapeutic efficacy of MSCs (Zappia eta;l2005).  This effect 
was associated with immune suppression of effector T cells leading to IL-2 reversible T- cell 
anergy. Subsequently, it was reported that MSCs inhibited T-cell activation with reduced IL-
17 and TNFǂ levels via the secretion of CCL2 by MSCs (Rafie  et al;2009)The preclinical 
studies, .( Asano  et al; 2006, Draper etal,2004, Lee et al;2001). 
 
 
Fig. 3. The immunomodulatory effect of MSCs. (a) A number of soluble factors secreted by 
MSCs can suppress the activity of inflammatory immune cells. (b) This suppressive activity 
can be enhanced by the presence of pro-inflammatory cytokines secreted by immune cells 
such as IFN-g. (c) The proportion of regulatory T cells and levels of IL-10 production are 
increased by MSCs. MSCs induce a bias towards a Th2 response and upregulate the 
production of IL-4. The production of IFN-g by Th1 cells is reduced. MSCs suppress CD8   T 
cells prior to activation and reduce production of IL-5 and IFN-g. (d) MSCs can reduce the 
production of IFN-g by NK cells. (e) DC differentiation, maturation and antigen 
presentation is inhibited by MSCs. The production of pro-inflammatory cytokines is 
reduced while IL-10 production is upregulated. (f) At high concentrations MSCs inhibit 
proliferationof B-cells, reduce the levels of IgM, IgG and IgA and downregulate the 
expression of several cytokine receptors (Payne et al;2008) 
Together with the cumulative data from ongoing clinical trials with MSCs in various clinical 
conditions (reviewed by Giordano et al2007), provided the scientific basis for many (Karussis 
et al ;2010,Mohyeddin Bonab et al ;2007, Riordan  et al;2009). phase 1/2 pilot clinical trial 
using combined intrathecal and / or intravenous injection of bone marrow– derived 
autologous MSCs  which preliminary prove the feasibility and safety of this type of cell 
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therapy,in the form of early clinical stabilization or improvement in some of the patients 
which could be related to these immunomodulating effects and he possibility of 
neuroprotection and neuroregeneration through transdifferentiation of MSCs into cells of 
the neuronal or glial lineage, although Further controlled trials are warranted to evaluate 
the long term safety and the potential clinical efficacy of MSC transplantation.The current 
data indicate that MSCs represent a promising alternative strategy in the treatment of  MS 
however, Many questions remain to be addressed, about a better understanding of the 
underlying mechanisms of immuno suppression as well as satisfying safety concerns as 
regards the in vivo survival, formation of ectopic tissue and malignant transformation. 
3.10 Stroke 
3.10.1 Introduction 
Stoke is the third leading cause of death in the USA and can be caused by the occlusion of 
small vessels in the brain that resulting in subsequent neuronal death. This will trigger a 
cascade of events including a wide spread inflammatory response. Current therapies for 
ischemic insults include thrombolysis through treatment with tissue plasminogen activator 
(tPA). (Bliss etal;2010).Stem cell transplantation offers an exciting new therapeutic avenue 
for stroke not only to prevent damage, which has been the focus of conventional therapeutic 
strategies, but also to actually repair the injured brain in ischemic(Bliss et al., 2007) and 
hemorrhagic stroke (Andres et al., 2008). 
3.10.2 Theraputic time window for stem cell therapy in stroke patients 
The majority of pre-clinical studies transplanted the stem cells within the first 3 days after 
stroke and they have mostly used bone marrow- or blood-derived cells (Bliss et al., 2007; 
Locatelli et al., 2009). This time window is greater than the 3- to 6-h window required for t-
PA therapy, the only treatment for stroke that currently exists. Cell enhanced recovery has 
also been reported with sub-acute (1 week post-stroke) and chronic (3 weeks post-stroke) 
delivery of many cell types including neural cells (Borlongan et al., 1998; Chen et al., 
2001a,b; Daadi et al., 2008; Shen et al., 2007; Zhao et al., 2002). Comparison of the results to 
identify an optimum time for transplantation is difficult as the studies used different models 
of stroke, cell types, methods of cell delivery, and behavioral tests to assess efficacy. The 
optimum time for transplantation may be dependent on (a) the cell type used , (b) their 
mechanism of action. If the treatment strategy is focused on neuroprotective mechanisms, 
the acute delivery will be critical, however, if the cells transplanted were meant to enhance 
endogenous repair mechanisms(e.g. plasticity and angiogenesis), then sub-acute delivery 
would be essential as these events are more prevalent in the first few weeks after ischemia 
(Carmichael, 2006; Hayashi et al., 2003), (c) route of administration such as  intravascular 
transplantation may require early administration as the cells use inflammatory signals to 
home to the injured brain (Guzman et al., 2008; Park et al., 2009; Pluchino et al., 2005) and 
(d) location of infarction , the majority of pre-clinical studies show cell-enhanced recovery 
after striatal lesions (Bliss et al., 2007; Guzman et al., 2008; Hicks and Jolkkonen, 2009; 
Locatelli et al., 2009) although cell-induced improvements with cortical lesions are also 
reported (Hicks et al., 2009; Shyu et al., 2006; Zhao et al.,2002). However, not all studies find 
that cell therapy is effective (Hicks et al., 2008).As shown in table (1) that  the timing of 
transplantation affected the outcome of these trials is not clear, but they at least demonstrate 
that delivery of cells at different times is feasible. 
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3.10.3 Ishemic versus haemorhagic stroke  
Ischemic and hemorrhagic strokes differ in their pathophysiology and mechanism of 
recovery (Xi et al., 2006). For example, there is no salvageable penumbra with intracerebral 
hemorrhage (ICH) unlike ischemic stroke (Qureshi et al., 1999), and patients with ICH do 
not suffer from reperfusion injury with its burst of free radical production (Kleinig and 
Vink, 2009). Toxic blood breakdown products like thrombin, hemoglobin, and iron 
additionally contribute to neuronal damage after ICH (Hua et al., 2007; Wang et al., 2002). 
Therefore, it is plausible that hemorrhagic and ischemic stroke may respond differently to 
cell therapy and should be tested separately in clinical trials (Andres et al., 2008; Wechsler et 
al., 2009).  
 
Clinical 
identifier and 
clinical phase 
Cell type 
Estimated 
enrollment 
Time of 
delivery* 
Route of 
delivery 
Country 
NCT0047357 
Phase I 
Autologous 
bone marrow 
10 
3h-90 
days 
Intra-arterial Brazil 
NCT00859014 
Phase I 
Autologous 
mononuclear 
bone marrow 
10 24 h-72 h Intravenous USA 
Nct00525197 
Phase I/II 
Autologous 
CD34 + bone 
marrow 
10 7 days Intra-arterial UK 
NCT00950521 
Phase II 
Autologous 
CD34 + 
peripheral 
blood 
30 
6-60 
months 
Intracerebral China 
NCT00875654 
Phase II 
Autologous 
MSCs 
30 < 6weeks Intravenous France 
Clinical identifier fromclinical trial gov; time of delivery after stroke onset  
Table 1. Current clinical cell transplantation trial for stroke 
3.10.4 Route of administration  
Many of the studies using systemic delivered cells find significant functional recovery with 
very few (Guzman et al., 2008; Hicks and Jolkkonen, 2009; Li et al., 2002; Vendrame et al., 
2004) or sometimes no cells (Borlongan et al., 2004) entering the brain. Modo et al. (2002) 
found equal functional recovery when cells were grafted in the ipsi- or contralesional 
hemispheres, the optimum route of human stem cell delivery has not been determined but 
will ultimately depend on the timing of delivery, the cell type used, and their mechanism of 
action.human bone marrow cells (HBMC), human umbilical cord blood cells (HUCBC), 
peripheral blood progenitor cells, and adipose tissue mesenchymal progenitor cells have all 
been reported to enhance recovery after stroke with intracerebral or intravascular delivery, 
and with acute (1 day), subacute (1 week), or chronic (1 month) delivery after stroke (Bliss et 
al., 2007, Guzman et al., 2008,Hicks &Jolkkonen;2009,Shen et al., 2007).The only clinical use 
of intravenous injection of ex vivo-cultured autologous MSCs for the treatment of stroke 
patients was reported by Bango, et,al, 2005. showed improvement in Neurological outcomes 
as determined by the Barthel index and modified Rankin score, Although this trial described 
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the success and safety of intravenous injection of ex vivo-cultured autologous MSCs, but 
only five patients were treated with MSCs and therefore the results should be interpreted 
with caution. Furthermore, evidence that the intravenously injected MSCs were biologically 
active is indirect and based on a presumed improved functional recovery ( Dekeyser; 2005) 
3.10.5 Stem cells types for treating stroke: Current developments  
A variety of human cell types have been tested in experimental stroke ( Bliss et al., 2007): (1) 
neural stem/progenitor cells,(2) immortalized cell lines ,(3) hematopoietic/endothelial 
progenitors and stromal cells isolated from bone marrow, umbilical cord blood, peripheral 
blood, or adipose tissue. To become a useful therapeutic option, cells must show efficacy, 
have a large expansion capacity in culture to meet the eventual clinical demand.Cell 
transplantation has shown much promise in experimental models of stroke with a diverse 
array of cell types which reported to enhance functional recovery after ischemic ( Bliss et al., 
2007) and hemorrhagic stroke ( Andres et al., 2008). Such results led to early Phase I and II 
clinical trials using a cell line of immature neurons (hNT) derived from a human 
teratocarcinoma, fetal porcine cells, or autologous mesenchymal stem cells (MSCs). These 
studies focused on the safety and feasibility of cell transplantation therapy. No cell-related 
adverse effects were reported with the hNT (Kondziolka et al., 2005, 2000) and MSC 
transplants (Bang et al., 2005). However, 2 out of the 5 patients receiving the porcine cells 
developed either seizures or aggravation of motor deficits (Savitz et al., 2005); the value of 
the cell therapy to these adverse effects is unclear. 
3.10.5 Potential mechanisms of transplanted cell-mediated  stroke recovery 
3.10.5.1 Induction of neurogenesis  and synapses formation 
Human NPCs form synapses with host circuits (Ishibashi et al., 2004; Daadi et al., 2009a), 
However, only very few synapses are seen, and recovery occurred too early to be 
attributable to newly formed neuronal connections (Englund et al., 2002, Song et al., 2002). 
3.10.5.2 Neuroprotective mechanism 
Through secretion of trophic factors such as vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), glial cell-derived neurotrophic factor (GDNF), and brain-
derived neurotrophic factor (BDNF) that are likely to contribute for recovery (Kurozumi et 
al., 2005; Llado et al., 2004). Li and Chopp, 2009 suggested that MSCs regulate the levels of 
cell death through release of trophic factors as well as altering the gap junction coupling 
between astrocytes, this allows these cells to respond more effectively to control damage  
3.10.5.3 Immunomodulation and anti-inflammatory mechanism 
Intravenous injection of HUCB  or direct injection of human MSCs  into the hippocampus 
after global ischemia lead to  down regulate many inflammatory and immune response 
genes and shifted the balance from a pro- to anti-inflammatory response (Ohtaki et al., 
2008).  
3.10.5.4 Induction of Angiogenesis 
Increased vascularization in the penumbra within a few days after stroke correlates with 
improved neurological recovery in stroke patients (Krupinski et al., 1993; Senior, 2001) 
transplanted cell-induced blood vessel formation has been reported with BMSCs, NPCs, 
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HUCBCs and cells from human peripheral blood (Chen et al., 2003; Horie et al., 2008; Shen 
et al., 2006; Shyu et al., 2006; Taguchi et al., 2004). 
3.10.5.5 Activation of endogenous restorative processes 
Induction of host brain plasticity and increase in endogenous brain structural plasticity and 
motor remapping after ischemia is postulated to underlie the spontaneous recovery seen 
after stroke (Benowitz and Carmichael, 2010; Carmichael, 2006;2008), and cell 
transplantation may enhance these process. HUCBCs increased sprouting of nerve fibers 
from the contralateral to the ischemic hemisphere (Xiao et al., 2005), a similar phenomenon 
recorded with fetal-derived NPCs (Daadi et al., 2009b, Horie et al., 2009). these restorative 
process  not well understood but may signify a natural repair mechanism of the brain that 
could be enhanced by transplanted cells. MSC-treated rats demonstrated elevated 
oligodendrocyte precursors, which increased in concert with enhanced white matter areas 
(Taguchi et al., 2004,Li et al., 2005, 2006; Shen et al., 2006).and also Xin et al., 2010, suggest 
that MSCs may also locally increase the levels of tPA in astrocytes around the stroke lesion 
and that this increases neuroprotection and enhances neurite outgrowth. 
The pre-clinical evidence shows great promise for cell transplantation as a therapy for 
stroke. While we can be cautiously optimistic about the reality of such a therapy, many 
fundamental questions related to the optimal patient (including age, sex, etiology, anatomic 
location and size of infarct, and medical history), the most appropriate cell type, cell dose, 
the timing of surgery, the route and site of delivery, the need for immunosuppression, and 
mechanism of action remain to be answered.  
3.11 Cerebral palsy 
3.11.1 Introduction 
Cerebral palsy is a group of brain diseases which produce chronic motor disability in 
children, that affect children from all countries and all ethnic backgrounds. The causes are 
quite varied and range from damage to the brain during pregnancy, labor or shortly 
following birth and  due to the increased survival of very premature infants, the incidence of 
cerebral palsy may be increasing. While premature infants and term infants who have 
suffered neonatal hypoxic–ischaemic (HI) injury represent only a minority of the total 
cerebral palsy population,( Bartley & Carroll.,2003) Maximum repair and regeneration for 
cerebral palsy patients as listed by Filip et al. (2004) include:treatment of any infections, 
chemical toxicities, heavy metal poisoning, Oxygen therapies, Neuroprotective diet and 
therapies that include antioxidant and  endogenous stem cell/stress reduction program that 
continues to promote repair and regeneration  
The similar logistics of stem cell therapy in ischemic stroke also applies for the management 
of cerebral palsy,however, studies in this population are sparse (Mueller et al., 2005). 
3.11.2 Stem cell therapy for cerebral palsy: Current development 
3.11.2.1 Human neural stem cells (hNSCs) 
hNSCs replaced lost cells in a newborn mouse model of brain damage. Mice received brain 
parenchymal or intraventricular injections of hNSCs derived from embryonic germ (EG) 
cells. The stem cells migrated away from the injection site they can survive and disseminate 
into the lesioned areas, differentiate into neuronal and glial cells and replace lost neurons 
(Mueller et al ;2005) 
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3.11.2.2 Human umbilical cord stem cells (hUCSC) 
1.5 million CD34+/CD133 human umbilical cord stem cells had been injected subcutaneous 
in adipose tissue adjacent to the umbilicus. Patient with CP experienced clinically significant 
improvements in cognitive and motor skill function following this. What is intriguing is that 
many of these children began demonstrating benefit within the first day or so of receiving 
the injection. The children who demonstrated improvement were infants and toddlers 
(Singh and Roy, 2008).Clearly too little time elapsed to attribute these positive changes to 
hUCSC migration to the brain, engraftment and proliferation, however, these early onset 
clinically significant improvements become explicable when viewed as the end result of 
growth factor and neurotrophin activity. The hUCSC deposited in adipose tissue causes 
adipocytes to synthesize blood brain barrier disruptive TNF-alpha and NGF. This would be 
consistent with published laboratory and animal studies, and with the rapid improvements 
seen in the treated children (Singh and Roy, 2008, Payne, 2005).Medical College of Georgia 
researchers are conducting the first FDA-approved clinical trial to determine whether an 
infusion of stem cells from umbilical cord blood can improve the quality of life for children 
with cerebral palsy. The study will include 40 children age 2-12 whose parents have stored 
cord blood at the Cord Blood Registry in Tucson, Ariz (Medical College of  Georgia, 2010).. 
3.11.2.3.Mesenchymal Bone Marrow stem cells (MSCs) 
Padma, 2005 use an intra-arterial infusion of autologous bone marrow stem cells to patients 
with static encephalopathy including cerebral palsy, it was found that this procedure was 
feasible, safe and caused improve in  neurological functional outcome Chen et al; 
2010,proved that MSC transplanted  to animal model of Periventricular white matter injury 
(PVWMI) in preterm infants may have been neuroprotective and indirectly contributed to 
brain repair which proved by in vivo MRI demonstrated that labeled cells migrated away 
from the injection site toward lesioned areas in both hemispheres, confirmed by microscopy 
postmortem, but double-labeling studies found little evidence of differentiation into neural 
phenotypes. By expert opinion Carroll and Mays (2011), stem cells may be beneficial in 
acute injuries of the CNS the biology of stem cells is not well enough understood in chronic 
injuries or disorders such as cerebral palsy. More work is required at the basic level of stem 
cell biology, in the development of animal models, and finally in well-conceived clinical 
trials. 
3.12 Spinal cord injury 
3.12.1 Introduction 
Spinal cord injuries result in long-term functional deficits as a result of the failure of severed 
adult CNS neurons to regrow long distances, connect to their original targets, and restore 
circuitry. Several factors are thought to contribute to the lack of regeneration of spinal cord 
axons. These include a reduction in the intrinsic growth capacity of adult CNS projection 
neurons, the presence of inhibitory cues derived from damaged CNS myelin, and the 
formation of a glial scar by local astrocytes in response to inflammatory stimuli (Fitch and 
Silver;2008).There is no cure, and the most common current treatment — high-dose 
methylprednisolone — is of questionable value (Lindvall & Kokaia;2006).Multiple 
approaches will be required to generate functional recovery. This hypothesis has recently 
received strong support from the use of combinatorial therapies directed at intrinsic and 
environmental regulators of regeneration Cell-based therapy is currently one of the   
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promising approachs as many studies have shown improvement in sensory or motor 
function in the presence of various types of grafted stem cells or ex vivo pre-differentiated 
stem cells (Kadoya et al., 2009). 
3.12.2 Rationales for therapeutic use of stem cells for SCI include (figure 4) 
3.12.2.1 Replacement of damaged neurons and glial cells 
One possible effect of cell therapy is “replacement,” meaning that the grafted cells integrate 
into the host tissue and replace damaged or lost cells. Several studies have been performed 
using in vitro expanded neural stem/progenitor cells, which were then implanted into 
injured animal model for spinal cord. The cells survived and differentiated into neurons, 
astrocytes, and oligodendrocytes and had a positive effect on functional outcome ( Ogawa et 
al;2002,Okada et al; 2005) Similarly, MSCs can also differentiate into neuron-like cells and 
glia  which stained for the neural proteins (Azizi;1998, Brazelton ;2000,  Prockop ;1997, 
Woodbury;2000, Okano ;2005 , Mezey; 2000, Hofstetter et al;2002)  
3.12.2.2 Environmental change in the spinal cord that would encourage regeneration 
Create a more favorable environment for limiting damage and promoting regeneration, via 
immunoregulation (Aggarwal & Pittenger, 2005; Noel et al., 2007), expression of growth 
factors and cytokines (Song et al., 2004), improved vascularization, providing a permissive 
growth substrate, and/or suppressing cavity formation (Hofstetter et al., 2002).  Enhance 
remylination  and increase the survival of oligodendrocytes  Zhang et al; 2008. 
3.12.2.3- cell fusion: The implanted adult stem cells may even fuse with the endogenous 
stem cells of the spinal cord. Some experiments have shown that MSCs have the ability to 
fuse with a variety of cells( Alvarez-Dolad;2003 ,Terada et al; 2002). Other studies have 
shown that cell fusion does not exist or if it does, it is specific to the liver ( Newsome et 
al;2003). This concept should be tested within the framework of spinal cord injury in the 
future.However,the attendant risks of stem cell therapy for SCI—including tumor 
formation, or abnormal circuit formation leading to dysfunction—must be weighed against 
the potential benefits of this approach.  
 
 
Fig. 4. Possible ways adult stem cells improve recovery in the injured spinal cord (Sherri & 
Schultz,2005) 
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3.12.3 Stem cell therapy of SCI: current development  
Cell-based therapy is currently a promising approach as many studies have shown 
improvement in sensory or motor function in the presence of various types of stem cells 
embryonic stem cells, Blesch  et al;2002 olfactory ensheathing glial cells, and Schwann cells 
(Lima;2006) The bone marrow also contains at least 2 discernable stem cell populations( 
Jiang et al;2002 , Mazurier  et al ;2003) 
3.12.3.1.Embryonic stem  (ES) cells 
Several studies have indicated that rodent ESC-derived neurons can survive, integrate and 
help restore function following transplantation into spinal cord injured rats (Finley et al., 
1996; Lang et al., 2004), Deshpande et al., 2006). Human ESCs have been directed to 
differentiate into multipotent neural precursors (Carpenter et al., 2001; Reubinoff et al., 
2001),and to high purity oligodendrocyte progenitors (Keirstead et al., 2005; Nistor et al., 
2005). embryonic and fetal neural stem cells demonstrated stability, sustainability, and 
expandability in long-term culture systems in order for them to be considered as a 
possibility in human application. However, serious ethical dilemmas, also lack the ease of 
accessibility and practicality limit the  routine clinical use (Reubinoff et al., 2001). 
3.12.3.2 Adult stem cells  
Unlike embryonal or fetal origin stem cells, using adult stem cells avoids ethical and moral 
problems as well as teratogenic and oncogenic risks, a variety of adult stem cells have been 
implanted in a rat model of spinal cord injury, ranging from olfactory ensheathing cells,and 
schwann cells (Lima etal;2010) cultured spinal cord stem cells, umbilical cord SC,  bone 
marrow derived stem cells, dermis derived stem cells ( Sahni & Kessler;2010) 
3.12.3.2.1 Human Neuronal stem cell (NSCs) 
NSCs have been preferred in SCI studies because NSCs have the definite ability to 
differentiate into functional neurons and glial cells after being transplanted in the injured 
spinal cord (Kim et al; 2007, Johnson et al; 2010. Mothe et al;2008) However, like embryonic 
stem cells, clinical application of adult NSCs, requires careful preclinical evaluation of their 
safety , efficacy,  purity of the neural cultures as well as there are bioethical issues to be 
considered (Daar et al;2004, Henon;2003, Riaz et al; 2002) 
3.12.3.2.2 Olfactory ensheathing glia cells (OEC’s) 
“OEC’s have been shown to penetrate the inhibitory glial scar at the injury site, and then 
migrate to their correct targets, restoring function. OEC’s could also provide an extracellular 
matrix and other types of neurotrophins to the injured neurons and neural differentiated 
adult stem cells, OECs are themselves not considered stem cells(Lima etal;2010). AS they are the 
patient’s own cells, there is no concern regarding rejection (Lima et al;2006).  
3.12.3.2.3 Human umbilical cord stem cells (hUCB) 
The hUCB cells are immune naïve and so they subsequently cause less graft rejection, GvHD 
and post-transplant infections (Knutsen & Wall;1999,Newcomb et al ; 2007, Tse & Laughlin; 
2005,) and they are able to differentiate into  neural lineage. Evidence has emerged 
suggesting alternative pathways of graft-mediated neural repair that involve neurotrophic 
effects. These effects are caused by the release of various growth factors that promote cell 
survival, angiogenesis and anti-inflammation, and this is all a side from a cell replacement 
mechanism (Park et al ; 2011), Willing  and his colleague (2003) prove that,  hUCB cells can 
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be administered by an intraarterial or intravenous route as well as by the direct intralesional 
approach. Intravenous injection of mononuclear hUCB cells was at least as effective and/or 
more effective at some points than direct  implantation. 
3.12.3.2.4 Mesenchymal stem cells (MSCs) 
Autologous bone marrow- derived stem cells are ideal candidates for treating SCI in 
emerging clinical studies, because there are no ethical obstacles to their use and the health 
risk for patients with SCI is rather small (Park et al; 2005). Numerous electrophysiological 
and histological preclinical studies have revealed  feasibility and beneficial potential of  
implantation of stem cells from bone marrow in animal models of SCI which showed, 
neuronal and axonal regeneration, astrocyte proliferation, remyelination, 
neovascularization, and functional improvement (Akiyama et al ;2002a,b, Chopp et al ;2000, 
Hofstetter et al;2002, Inoue et al;2003, Jendelova´et al;2004, Kalyani et al;1998, Saporta 
etal;2003, Sykova´& Jendelova´;2006 &2005, Sykova´ et al; 2005, Urdzı´kova´et al;2006, Wu et 
al ;2003). These studies have also shown that the optimal therapeutic window for 
implantation in animal  models of SCI is 7–21 days after injury. As regard mode of cell 
delivery preclinical experiments in rats with SCI demonstrated that intravenously 
implanted human bone marrow-MSCs labeled in vitro with iron oxide nanoparticles and 
followed in vivo by magnetic resonance imaging (MRI), migrate, survive, and home only to 
the lesion site (Jendelova´et al;2004, Sykova´& Jendelova´;2005). All these data encourage 
scientists to initiate many nonrandomized phase I/II clinical studies  using autologousBM-
MSCs ,delivered to the patient by many routes ( Geffner et al ;2008) either implanted direct 
intralesional Park and colleagues 2005  or intra- arterially via a. vertebralis (i.e., close to the 
lesion site) (Sykova et al ;2006 )or  less invasive  which include intravenous, or Intrathecal 
(Bakshi et al ;2006 , Kishk, et,al2010) into patients with subacute (Park et al ;2005, 
Sykovaet,al2006) or chronic SCI (Sykova etal;2006 , Kishk, et al;2010 )at the cervical or 
thoracic level, the outcome from BMMC implantation in acute and  chronic patients is 
promising .however, the therapeutic window will play an important role in any type of SCI 
treatment. There seems to be a similar therapeutic window in humans as in animals, which 
is up to 3–4 weeks after SCI. Sykova and his colleague ;2006 suggest that administering the 
cells closer to the injury site, such as through the catheterization of a. vertebralis, or into the 
cerebrospinal fluid (Kishk et al; 2010,Ohata et al; 2004), or even intraspinally at the lesion 
border (Park et al; 2005), might be important for a better outcome. The observed partial 
recovery might be attributable to a “rescue effect,” a reduction in tissue loss from secondary 
injury processes, as well as to diminished glial scarring. MSCs may induce an allodynia-like 
response by producing intrathecal proinflammatory cytokines, especially interleukin-1, 
tumor necrosis factor, and interleukin-6 (. Chae etal; 2009). Neither Abrams et al;2009,  
Sykova et al;2006 or Geffner et al; 2008 reported central pain as a complication. The 
deployment of MSCs in patients with subacute or chronic traumatic SCI will need  longer 
follow-up, more studies that explore the best timing post injury , the dose and duration of 
MSC interventions, Objective assessment of the bladder and bowel function with 
urodynamic studies and anal sphincter EMG is necessary. Imaging of the lesions by MRI 
using particle-labeled MSCs could determine whether the cells reach the lesion. Future in 
vivo markers for neuronal regeneration or remyelination could give more insight into the 
mechanisms of any biological effects  (Dobkin 2010) 
Clinical studies are necessary , However, the question of which cell type is most beneficial 
for SCI treatment is still unresolved as what are the mechanisms underlying the beneficial 
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effect(s)  The therapeutic window, the implantation strategy, the method of administration, 
the number of cells, and the possible side effects can only be tested in human clinical trials 
guided by  Guidelines for trials of cellular therapies (Fawcett etal;2007) . 
4. Conclusion 
It is realistic to believe that stem cells will be used clinically, not as a cure-all but as part of a 
therapeutic armamentarium The key, however, will be in applying the right cell type to the 
right disease and conveying the right amount of expectation to the patient. Meticulous 
attention to the ethics and Collaboration between basic scientists, clinicians, industry 
partners, and funding bodies is required to translate the potential of cell therapy into a 
reality in a timely, but safe and effective manner . 
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